Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
92.38(c) 91.42(c) 90.67(c) 91.04(c) 92.17(c) Last
6 298 549 4 818 207 6 803 873 4 640 276 5 239 293 Volume
+1.33% -1.04% -0.82% +0.41% +1.24% Change
More quotes
Financials ($)
Sales 2017 27 965 M
EBIT 2017 11 934 M
Net income 2017 7 394 M
Debt 2017 25 874 M
Yield 2017 2,85%
Sales 2018 30 895 M
EBIT 2018 13 823 M
Net income 2018 9 089 M
Debt 2018 22 120 M
Yield 2018 3,18%
P/E ratio 2017 19,53
P/E ratio 2018 15,75
EV / Sales2017 6,11x
EV / Sales2018 5,41x
Capitalization 145 B
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
10/13 ABBVIE : obtains licence for Turnstone Biologics oncolytic viral immunotherapies
10/13 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at..
10/12 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/12 ABBVIE : ex-dividend day
10/11 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pib..
10/11 ABBVIE : ABBV), Turnstone Biologics Announce Pact on Viral Immunotherapies in On..
10/11 ABBVIE : Dividend Coverage: This Pharmaceutical Company has Raised Dividend By 6..
10/11 ABBVIE : to Host Third - Quarter 2017 Earnings Conference Call
10/11 ABBVIE : jumps on the oncolytics bandwagon, embracing Turnstone in new collabora..
10/10 ABBVIE : Collierville man awarded $140 million in lawsuit over testosterone drug..
More news
Sector news : Specialty & Advanced Pharmaceuticals
08:48aDJDaimler Charts Leaner Approach -- WSJ
08:46aDJASTRAZENECA : FDA Accepts Imfinzi Supplemental Biologics License Application; Gr..
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16DJDaimler Reshapes Company to Meet Challenges of Changing Industry -- Update
10/16 Miners provide foundation for FTSE while ConvaTec plummets
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE 
ABBVIE  - 2015
A likely recovery
BUY
More Strategies
Latest Tweets
10/16Just noticed $ABBV market cap at $145 Billion. Insane !
1
10/16Abbvie $ABBV PT Raised to $115 at Jefferies  
10/16TG Therapeutics down 20% premarket on potential extended timeline for U.S. ma.. 
10/16AbbVie's PT raised by Jefferies Group LLC to $115.00. buy rating.  
10/16Bristol-Myers downgraded to Hold from Buy at Jefferies $BMY $ABBV
3
More tweets
Qtime:262
News from SeekingAlpha
10/16 BIOTECH FORUM DAILY DIGEST : Aratana Therapeutics Back In The Spotlight
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 TG Therapeutics down 20% premarket on potential extended timeline for U.S. ma..
10/13 ROCHE AND ALLERGAN : Approaches To Alzheimer's
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 92,7 $
Spread / Average Target 1,8%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE44.79%145 126
MERCK KGAA-2.27%14 717
KYOWA HAKKO KIRIN CO LTD23.05%10 210
JAZZ PHARMACEUTICALS PLC29.67%8 492
CONVATEC GROUP19.41%7 227
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD29.42%5 435